This triple mechanism distinguishes retatrutide from existing approved weight loss peptides such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist), although direct head-to-head trials comparing these agents have not been conducted, and comparative efficacy has not been established
53 A alleles, p = 0.41, odds ratio 0.93, 95% C.I
The complete guide Why does semaglutide cause yeast infections
Another limitation is the chosen nomenclature
The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss
When medications mimic or enhance these signals, the body begins responding differently to food intake